Insight · Industry Report
Annex 1 and Pre-Filled Syringes: What Changed, What to Do
The EU GMP Annex 1 revision tightens contamination control for sterile manufacturing. Here is what it means for PFS lines.
Key Takeaway
The EU GMP Annex 1 revision tightens contamination control for sterile manufacturing. Here is what it means for PFS lines.
The revised EU GMP Annex 1 (effective August 2023) has reshaped how pre-filled syringe lines are designed and qualified. The headline change: a mandatory Contamination Control Strategy (CCS) covering every step from incoming components to final sterile closure.
Key implications for PFS lines:
- Isolator or RABS is now the de-facto baseline
- Pre-use post-sterilization integrity testing (PUPSIT) for sterilizing filters
- Continuous viable and non-viable particle monitoring
- Documented contamination control strategy reviewed by quality
Manufacturers retrofitting older filling lines should plan for 9–18 months of upgrade and re-qualification.
About NovalineX
NovalineX helps investors develop bankable medical manufacturing projects across Africa, the Middle East, Asia, and emerging markets.
Interested in developing a medical manufacturing project?
Contact NovalineX for a preliminary project assessmentServices include
- Syringe Manufacturing Plants
- IV Solution Production Facilities
- Blood Collection Tube Projects
- GMP Planning
- ISO 13485 Compliance Support
- ROI & Feasibility Analysis
- Utility & Factory Layout Review
Next Step · Move Your Project Forward
Ready to advance your syringe factory project to bankable stage?
NovalineX delivers full bankability assessments, PPR preparation, GMP facility design, and turnkey production line execution — tailored to your market, scale, and financing plan.